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A B S T R A C T
We present a review of critical concepts and produce recommendations on the management of
Philadelphia-negative classical myeloproliferative neoplasms, including monitoring, response defini-
tion, first- and second-line therapy, and therapy for special issues. Key questions were selected
according the criterion of clinical relevance. Statements were produced using a Delphi process, and
two consensus conferences involving a panel of 21 experts appointed by the European LeukemiaNet
(ELN) were convened. Patients with polycythemia vera (PV) and essential thrombocythemia (ET)
should be defined as high risk if age is greater than 60 years or there is a history of previous
thrombosis. Risk stratification in primary myelofibrosis (PMF) should start with the International
Prognostic Scoring System (IPSS) for newly diagnosed patients and dynamic IPSS for patients being
seen during their disease course, with the addition of cytogenetics evaluation and transfusion status.
High-risk patients with PV should be managed with phlebotomy, low-dose aspirin, and cytoreduction,
with either hydroxyurea or interferon at any age. High-risk patients with ET should be managed with
cytoreduction, using hydroxyurea at any age. Monitoring response in PV and ET should use the ELN
clinicohematologic criteria. Corticosteroids, androgens, erythropoiesis-stimulating agents, and immu-
nomodulators are recommended to treat anemia of PMF, whereas hydroxyurea is the first-line
treatment of PMF-associated splenomegaly. Indications for splenectomy include symptomatic portal
hypertension, drug-refractory painful splenomegaly, and frequent RBC transfusions. The risk of
allogeneic stem-cell transplantation–related complications is justified in transplantation-eligible patients
whose median survival time is expected to be less than 5 years.
J Clin Oncol 29:761-770. © 2011 by American Society of Clinical Oncology
INTRODUCTION
The discovery that the protein tyrosine kinase JAK2
is mutated (V617F) in more than 90% of patients
with polycythemia vera (PV) and approximately
60% of patients with essential thrombocythemia
(ET)orprimarymyelofibrosis (PMF)1 hasmodified
our understanding of the clinical and biologic fea-
tures of thePhiladelphia (Ph) -negative classicalmy-
eloproliferative neoplasms (MPNs). It is now clear
that patients with the mutation are biologically dis-
tinct from those without the mutation and that the
mutation is associated with different disease pheno-
types. These new concepts have modified our crite-
ria for diagnosis, the strategies for monitoring, and
the tools for assessing the response to treatments.
The discovery of JAK2 activating mutations in Ph-
negative classical MPNs also spurred the develop-
ment of small-molecule inhibitors that specifically
target JAK2.2 However, this discovery has not yet
translated into changes in the management of the
three disorders. Thus, the therapy of Ph-negative
classical MPNs remains a challenging enterprise re-
quiring ahighdegreeof professional experience. For
these reasons, the European LeukemiaNet (ELN)
decided to review recent data regarding therapy,
standardmonitoring procedures, and definitions of
responses and to produce recommendations aimed
at contributing to theoptimizationandstandardiza-
tion of management of the three Ph-negative classi-
cal MPNs.
THE CONSENSUS PROCESS
An expert panel (hereafter referred to as the Panel)
of 21 experts was selected for their expertise in re-
search and clinical practice of management of Ph-
negative classical MPNs. During an initial meeting
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held inNewOrleans, Louisiana, inDecember 2009, the areas ofmajor
concern in the management of Ph-negative classical MPNs were se-
lectedby generating and rankordering clinical keyquestionsusing the
criterionof clinical relevance, throughgroupdiscussion.Twenty-nine
candidate key questions were generated, and after discussion, the 25
that rankedhighest formed the set of questionsof thepresent concepts
and recommendations.
Two panelists drafted statements that addressed the identified
key questions, and the remaining panelists scored their agreement
with those statements and provided suggestions for rephrasing. For
exploiting this phase of the process, theDelphi questionnairemethod
was used.3 Finally, the Panel convened once again for a consensus
conferenceheld inBarcelona, Spain, in June2010.Thenominal group
techniquewasusedbywhichparticipantswerefirst asked to comment
inround-robin fashionontheirpreliminaryvotesandthen topropose
a new vote.4 For five of 25 statements produced, no consensus was
achieved at first, and these statements were rediscussed. At the second
vote, all of the statements were decided.
CRITICAL CONCEPTS
Diagnosis
Standard and uniform diagnostic criteria for Ph-negative classi-
calMPNs are essential for clinical research, case reporting, and clinical
practice. The 2008 WHO classification and diagnosis criteria meet
these requirements (Table 1).5 Some investigators remain loyal to red
cellmassmeasurement as adiagnostic tool forPV,6whereas others are
skeptical about the use of morphology in distinguishing ET from
prefibrotic PMF.7 The WHO classification system addresses both is-
sues by allowing the diagnostic use of the red cell mass, when desired,
and the incorporation of biologically relevant minor criteria to con-
firm histologic impression for prefibrotic PMF.
Patient Communication
Mediansurvival inPVandETapproachesorexceeds20years,8-11
and median survival in PMF is currently estimated at greater than 10
years.12 This news should be underscored to patients as soon as diag-
nosis is established. At the same time, potentially life-threatening (eg,
leukemic or fibrotic transformation, thrombohemorrhagic events)
and non–life-threatening (eg, poor quality of life from constitutional
symptoms, microvascular disturbances, pruritus, increased risk of
miscarriage) disease complications and their likelihood of response to
treatment shouldbedisclosed.Therapeutic optionsmust bediscussed
with thepatient, alongwith comments regardinghowboth thedisease
and its treatment will affect the patient’s quality of life.
Risk Classification
Because the current therapy in PV and ET is aimed at lowering
the risk of thrombosis, the risk classification system in these disorders
is shaped according to thrombosis risk. Several prospective and retro-
spective cohort studies in PV andEThave identified age older than 60
years and previous thrombosis as major predictors of vascular
complications.11,13-17 A clear association between platelet counts and
major vascular events is lacking, but extreme thrombocytosis (ie,
 1,500  109/L) can be associated with acquired von Willebrand
disease andbleeding tendency.18 Patients enrolled onto the Low-Dose
Aspirin in Polycythemia Vera (ECLAP) study failed to show any
correlation between hematocrit levels up to 50% and thrombosis.19
Risk stratification in PMF is addressed to death from any cause.
The International Prognostic Scoring System (IPSS) uses variables
obtained at time of diagnosis (Table 2),20 and the same IPSS prognos-
tic variables are used to stratify patients seen at any time during their
disease course (dynamic IPSS).21 Recent studies have demonstrated
that transfusion need in the first year of diagnosis or the presence of
cytogenetic abnormalities other than sole9, 13q–, or 20q– identifies
patientswithmedian survivalof less than5years.22,23 In theaforemen-
tioned IPSS study,20 thepresenceof JAK2V617Fdidnot correlatewith
either survival or IPSS score. This lack of prognostic relevance in
regard topresenceor absenceof JAK2V617Fwas alsodemonstrated in
two recent large studies, which instead showed shortened overall sur-
vival in patients with PMF with lower as opposed to higher quartile
JAK2V617F allele burden.24,25
Table 1. Diagnostic Criteria for Philadelphia-Negative Classical Myeloproliferative Neoplasms According to WHO (2008)
Myeloproliferative
Neoplasm Criteria
Polycythemia vera
Major criteria Hemoglobin  18.5 g/dL in men or 16.5 g/dL in women or other evidence of increased RBC volume; presence of JAK2V617F or
other functionally similar mutation such as JAK2 exon 12 mutation
Minor criteria Bone marrow biopsy showing hypercellularity for age with trilineage growth (panmyelosis) with prominent erythroid, granulocytic,
and megakaryocytic proliferation; serum erythropoietin level below the reference range for normal; endogenous erythroid colony
formation in vitro
Essential
thrombocythemia†
Sustained platelet count  450  109/L; bone marrow biopsy specimen showing proliferation mainly of the megakaryocytic lineage
with increased numbers of enlarged, mature megakaryocytes; no significant increase or left shift of neutrophil granulopoiesis or
erythropoiesis; not meeting WHO criteria for polycythemia vera, primary myelofibrosis, BCR-ABL1–positive chronic myelogenous
leukemia, myelodysplastic syndrome, or other myeloid neoplasm; demonstration of JAK2V617F or other clonal marker, or in the
absence of JAK2V617F, no evidence for reactive thrombocytosis
Primary myelofibrosis‡
Major criteria Presence of megakaryocyte proliferation and atypia, usually accompanied by either reticulin and/or collagen fibrosis, or in absence
of significant reticulin fibrosis, a prefibrotic cellular-phase disease; not meeting WHO criteria for polycythemia vera, BCR-ABL1–
positive chronic myelogenous leukemia, myelodysplastic syndrome, or other myeloid neoplasm; demonstration of JAK2V617F or
other clonal marker (eg, MPLW515K/L), or in absence of clonal marker, no evidence of secondary bone marrow fibrosis
Minor criteria Leukoerythroblastosis; increase in serum lactate dehydrogenase level; anemia; splenomegaly
Diagnosis requires the presence of both major criteria and one minor criterion or the presence of the first major criterion together with two minor criteria.
†Diagnosis requires meeting all four criteria.
‡Diagnosis requires meeting all three major and two minor criteria.
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Goal of Therapy
Goals of therapy in patients with PV and ET are to avoid first
occurrence and/or recurrence of thrombotic and bleeding complica-
tions; tominimize the risk of acute leukemia and post-PV/ETmyelo-
fibrosis; and to control systemic symptoms, treat complications
(thrombosis and hemorrhage), and manage risk situations (eg, preg-
nancy, surgery).Themaingoalsof therapy inPMFareprolongationof
survival and, if possible, also cure, which is currently only achieved by
allogeneic stem-cell transplantation (alloSCT). If prolongation of sur-
vival or cure is not possible, symptom-orientated palliation and qual-
ity of life are the main goals.
RECOMMENDATIONS
Investigations Before Planning Therapy
Information regarding variables used in the patient’s risk strati-
fication should be collected (ie, age and thrombotic history for PV;
age, thrombotic history, and platelet count for ET; and age, hemoglo-
bin, blast count,WBCcount, and constitutional symptoms for PMF).
It is also important to consider general risk factors for thrombosis,
including metabolic syndrome, diabetes mellitus, arterial hyperten-
sion, and hypercholesterolemia. The Panel agreed that obtaining ad-
ditional informationon transfusion status and cytogenetics is strongly
recommended inPMF, andperipheral-bloodCD34 count is auseful
biomarker of disease aggression.
Management of PV
First-line therapy. Recommendations on treatment strategy for
PV derive fromhistorical Polycythemia Vera StudyGroup, European
Organisation for Research and Treatment of Cancer, and French
Polycythemia Study Group trials26-30 and the more recent ECLAP
study.19 In the Polycythemia Vera Study Group trials, patients ran-
domly assigned to the phlebotomy arm had a better median survival
time than patients assigned to the chlorambucil or radiophosphorus
arms because of the high frequency of acute leukemia in the latter two
arms. However, overall long-term survival at 10 years showed no
statistical significant difference between phosphorus-32 (32P) and
phlebotomy. In patients given hydroxyurea, the incidence of throm-
bosis was inferior to historical controls treated with phlebotomy. The
European Organisation for Research and Treatment of Cancer trial
compared 32P with intermittent busulphan, and the overall survival
was significantly better in thebusulphanarmas a result of less vascular
deaths. Patients with PV enrolled onto the ECLAP study were ran-
domly assigned to receive aspirin 100mgorplacebo.After a follow-up
of approximately 3 years, data analysis showed a significant reduction
of events on aspirin.Major bleedingwas not significantly increased by
aspirin. Interferon alfa-2 (IFN--2) has been used in therapy of PV
showing up to an 80% hematologic response rate.31 Pegylated IFN-
has been demonstrated in phase II trials of patients with PV to have
clinical efficacy as measured by normalization of myeloproliferation,
lack of vascular events while on therapy, and a decrease in the
JAK2V617F allele burden.32
All patients with PV should be managed with phlebotomy to
maintain the hematocrit at less than 45% and low-dose aspirin. Cy-
toreduction is indicated in high-risk patients. Poor tolerance of
phlebotomy or frequent phlebotomy requirement, symptomatic or
progressive splenomegaly, severe disease-related symptoms, platelet
counts greater than 1,500  109/L, and progressive leukocytosis are
indications for cytoreductive therapy. Either hydroxyurea or IFN- is
first-line cytoreductive therapy at any age. Hydroxyurea should be
used with caution in young patients (ie, age 40 years). Busulphan
may be considered in elderly patients (ie, age 70 years). All patients
should be managed aggressively for their generic cardiovascular risk
factors and advised to stop smoking.Theuse of cytoreductive drugs in
otherwise low-risk patients who have well-controlled cardiovascular
risk factors is not indicated.
Monitoring response. Monitoring of response to conventional
cytoreductive therapy of individual patientswith PV should adopt the
ELN criteria proposed for defining the clinicohematologic response33
(Table 3). There is no strict indication tomonitormolecular response
routinely, including sequential assessment of the JAK2V617F allele
burden, except if the therapeutic intervention may induce molecular
responses (to date IFN-), and no indication to monitor bone mar-
row response for clinical follow-up.
Table 2. International Prognostic Scoring System Adverse Prognostic
Factors for Primary Myelofibrosis
Adverse Prognostic Factors
Age  65 years
Constitutional symptoms
Hemoglobin  10 g/dL
WBC count  25  109/L
Blood blasts  1%
NOTE. On the basis of the presence of zero (low risk), one (intermediate
risk-1), two (intermediate risk-2), or  three (high risk) of these variables, four
risk groups are delineated.
Table 3. European LeukemiaNet Definition of Clinicohematologic Response in Polycythemia Vera and Essential Thrombocythemia
Response Grade Definition of Response in Polycythemia Vera Definition of Response in Essential Thrombocythemia
Complete response 1. Hematocrit  45% without phlebotomy, AND
2. Platelet count  400  109/L, AND
3. WBC count  10  109/L, AND
4. Normal spleen size on imaging, AND
5. No disease-related symptoms
1. Platelet count  400  109/L, AND
2. No disease-related symptoms, AND
3. Normal spleen size on imaging, AND
4. WBC count  10  109/L
Partial response In patients who do not fulfill the criteria for complete response:
1. Hematocrit  45% without phlebotomy, OR
2. Response in  3 of the other criteria
In patients who do not fulfill the criteria for complete response:
platelet count  600  109/L or decrease of  50% from
baseline
No response Any response that does not satisfy partial response Any response that does not satisfy partial response
Disease-related symptoms include microvascular disturbances, pruritus, and headache.
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Therapy change and second-line therapy. The choice of second-
line myelosuppressive drugs for PV should be carefully evaluated
because somedrugs administered after hydroxyureamay enhance the
risk of acute leukemia.34 IFN- should be considered because this
drug is reported to be nonleukemogenic.
Low-risk patients with PV who are  60 years old or develop
major thrombotic or hemorrhagic complications require the intro-
duction of cytoreductive therapy. In such patients, progressively
increasing leukocyte and/or platelet count, enlarging spleen, uncon-
trolled disease-related symptoms, and poorly tolerated phlebotomy
regimenmay also justify the introduction of cytoreductive therapy. In
high-risk patients, first-line therapy should be changed when intoler-
ancehasbeendemonstrated (Table4).35Aspirin shouldbewithdrawn
in the event ofmajor bleeding,most frequentlyGI, or in the rare cases
of allergy or intolerance. Second-line therapy of PV is IFN- in pa-
tients intolerant or resistant to hydroxyurea therapy. Conversely, hy-
droxyurea is the second-line therapy for patientswhoare intolerant or
refractory to first-line therapy with IFN-. Pipobroman, busulphan,
and 32P are second-line therapies reserved for patients with short
life expectancy.
Management of ET
First-line therapy. Recommendations on treatment strategy for
ET derive from two randomized controlled trials in high-risk pa-
tients36,37 and a case-control study in low-risk patients.38 In high-risk
patients, Cortelazzo et al36 showed that hydroxyurea lowers throm-
botic complications compared with no treatment. In the Primary
Thrombocythemia1Trial (PT-1),37hydroxyureaplusaspirin reduced
a composite end point of arterial and venous thrombosis—major
bleeding or death from thrombotic or hemorrhagic causes—
compared with anagrelide plus aspirin. In untreated low-risk pa-
tients, the incidence of thrombosis was similar to that observed in
a healthy control population.14,38,39
All patients with ET should bemanaged with low-dose aspirin if
microvascular disturbances are present. Cytoreduction is indicated in
high-risk patients. Hydroxyurea is the first-line cytoreductive therapy
at any age; in young patients ( 40 years old), its use should be
carefully considered. All patients should be managed aggressively for
their cardiovascular risk factors and advised to stop smoking. The use
of cytoreductive drugs in otherwise low-risk patients having well-
controlled cardiovascular risk factors is not generally indicated. Plate-
let count greater than 1,500 109/L is a risk factor for bleeding, and at
this level of thrombocytosis, a platelet-lowering treatment should
be considered.
Monitoring response. Clinicohematologic,molecular, andhisto-
logic response criteria for ET have been identified by ELN experts for
application in clinical trials.33 The response of therapy should be
evaluated by normalization of blood counts and disappearance of
signs and symptoms of disease (Table 3). There is no indication to
monitor bone marrow response for clinical follow-up. Bone marrow
aspirate and trephine biopsy are useful in assessinghematologic trans-
formation to myelofibrosis or acute leukemia. There is no strict indi-
cation tomonitor molecular response routinely, including sequential
assessment of the JAK2V617F allele burden.
Therapy change and second-line therapy. Patients with ET who
receive more than one cytotoxic agent do have a significantly higher
risk of developing acute myeloid leukemia/myelodysplastic syn-
dromes.40,41 For this reason, in patients resistant or intolerant to
first-line therapywithhydroxyurea,42 nonleukemogenicdrugs suchas
anagrelide or IFN should be considered.
Low-risk untreated patients should start a cytoreductive treat-
ment as soon as they move to the high-risk category as a result of
increasing age, the occurrence of amajor thrombotic or hemorrhagic
event, or increasing platelet count greater than 1,500  109/L. In
high-risk patients, treatment with hydroxyurea should be changed in
case of intolerance (Table 4). In patients with disease resistant to
hydroxyurea, changing therapy may be an option. Although less fre-
quently than in PV, cytoreduction may also be required for progres-
sivemyeloproliferation (eg, increasing splenomegaly)oruncontrolled
systemic symptoms. Aspirin should be withdrawn in case of major
bleeding, most frequently GI, or in the rare cases of allergy or intoler-
ance.Anagrelide is the recommended second-line therapy forET. IFN
is an experimental therapy and should be reserved for selected pa-
tients, such as young females or patients who have contraindications
to anagrelide therapy. Pipobroman, busulphan, and 32P are second-
line therapies reserved for patients with short life expectancy.
Table 4. European LeukemiaNet Definition of Resistance/Intolerance to Hydroxyurea in Patients With Polycythemia Vera and Essential Thrombocythemia
Myeloproliferative Neoplasm Definition of Resistance/Intolerance to Hydroxyurea
Polycythemia vera 1. Need for phlebotomy to keep hematocrit  45% after 3 months of at least 2 g/d of hydroxyurea, OR
2. Uncontrolled myeloproliferation (ie, platelet count  400  109/L AND WBC count  10  109/L) after 3 months of
at least 2 g/d of hydroxyurea, OR
3. Failure to reduce massive splenomegaly by  50% as measured by palpation OR failure to completely relieve
symptoms related to splenomegaly after 3 months of at least 2 g/d of hydroxyurea, OR
4. Absolute neutrophil count  1.0  109/L OR platelet count  100  109/L OR hemoglobin  10 g/dL at the lowest
dose of hydroxyurea required to achieve a complete or partial clinicohematologic response,† OR
5. Presence of leg ulcers or other unacceptable hydroxyurea-related nonhematologic toxicities, such as mucocutaneous
manifestations, GI symptoms, pneumonitis, or fever at any dose of hydroxyurea
Essential thrombocythemia 1. Platelet count  600  109/L after 3 months of at least 2 g/d of hydroxyurea (2.5 g/d in patients with a body weight
 80 kg), OR
2. Platelet count  400  109/L and WBC count  2.5  109/L at any dose of hydroxyurea, OR
3. Platelet count  400  109/L and hemoglobin  10 g/dL at any dose of hydroxyurea, OR
4. Presence of leg ulcers or other unacceptable mucocutaneous manifestations at any dose of hydroxyurea, OR
5. Hydroxyurea-related fever
Organ extending by  10 cm from the costal margin.
†Complete response is defined as hematocrit less than 45% without phlebotomy, platelet count  400  109/L, WBC count  10  109/L, and no disease-related
symptoms. Partial response is defined as hematocrit less than 45% without phlebotomy or response in three or more of the other criteria.
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Management of PMF
Patients with PMF face a umber of clinical issues (Table 5). Clinical
issues should be identified early and managed appropriately. Treat-
ment is neither always indicated nor similar across the different as-
pects of the disease.
How to treat anemia. Drugs for the treatment of anemia inPMF
includeerythropoiesis-stimulatingagents, corticosteroids, androgens,
danazol, thalidomide, and lenalidomide.43-46 Single-agent corticoste-
roid (0.5 to 1.0mg/kg/d) or androgen therapy (eg, testosterone enan-
thate 400 to 600 mg weekly, oral fluoxymesterone 10 mg tid) or
danazol at a dose of 600 mg/d has been used in PMF with response
rates of 30% to 40%. Thalidomide at low doses (50 mg/d) and in
combinationwith corticosteroids (prednisone15 to30mg/d)47,48 and
lenalidomide in the presence of del(5)(q31)47-51 show response rates
of approximately 20%.
It is reasonable to initiate treatment for anemia in patients with a
hemoglobin value less than 10 g/dL. Four agents have proved to be
effective in the anemia of PMF; these are corticosteroids, androgens,
erythropoiesis-stimulating agents, and immunomodulators. All of
these agents have limitations, and there are no comparative trials. In
the presence of del(5q), lenalidomide is preferred. There are no firm
data to support the value of iron chelation therapy in PMF.
How to treat splenomegaly. The drug of choice for symptomatic
splenomegaly is hydroxyurea,which is alsoused for controlling symp-
tomatic thrombocytosis and/or leukocytosis.52,53 Reduction of spleen
volumewith hydroxyurea reportedly occurs in approximately 40%of
patients.52 Hydroxyurea-refractory disease35 is sometimes managed
by the use of alternative myelosuppressive agents including intrave-
nous cladribine (5 mg/m2/d in a 2-hour infusion for 5 consecutive
days to be repeated for four to six monthly cycles),54 oral melphalan
(2.5mg three times aweek),55,56 andoral busulphan (2 to 6mg/dwith
close monitoring of blood counts). In contrast, INF- therapy is
poorly tolerated and has limited efficacy in the treatment of PMF.57-59
Involved-field radiotherapy provides symptomatic relief of me-
chanical discomfort from hepatosplenomegaly. However, the re-
sponse is transient (medianduration, 3 to 6months) andnot useful to
provide a consistent relief of this disturbance. When used, splenic
irradiation is given in a total dose of 0.1 to 0.5Gy infive to 10 fractions
and is associated with a greater than 10%mortality rate from conse-
quences of cytopenia.60 Splenectomy is often considered for the treat-
ment of drug-refractory symptomatic splenomegaly and is discussed
further later.
Hydroxyurea is currently the first-line treatment of choice in
PMF-associated splenomegaly. Splenic radiation is only of transient
benefit, and splenectomy remains a viable treatment option for drug-
refractory splenomegaly.
How to treat constitutional symptoms. Currentdogma implicates
aberrant cytokineproduction tobe causally related toPMF-associated
constitutional symptoms and cachexia. Constitutional symptoms can
be severe in patients with PMF and must be considered a key treat-
ment indication. Constitutional symptoms often respond to treat-
ment directed at splenomegaly.
How to treat nonhepatosplenic hematopoiesis. The thoracic ver-
tebral columnis themost frequent siteofnonhepatosplenicextramed-
ullary hematopoiesis (EMH) in PMF. Other sites include lymph
nodes, lung, pleura, small bowel, peritoneum, urogenital tract, and
heart. When symptomatic, such occurrences are effectively treated
with low-dose radiation therapy (0.1 to 1 Gy in five to 10 fractions).
Low-dose radiation therapy is currently the treatment of choice for
PMF-associated nonhepatosplenic EMH.
Splenectomy. The perioperative mortality of splenectomy in
PMF is between 5% and 10%, and postsplenectomy complications
occur in approximately 50% of patients. Complications include sur-
gical site bleeding, thrombosis, subphrenic abscess, accelerated hepa-
tomegaly, extreme thrombocytosis, and leukocytosis with excess
blasts.Consideration for splenectomy requires goodperformance sta-
tus and absence of clinical or laboratory evidence of disseminated
intravascular coagulation.61,62
Indications for splenectomy include symptomatic portal hy-
pertension (eg, variceal bleeding, ascites), drug-refractory marked
splenomegaly that is either painful or associated with severe ca-
chexia, and established RBC transfusion-dependent anemia. In
contrast, severe thrombocytopenia is a marker of impending leu-
kemic transformation, and overall outcomemight not be favorably
affected by splenectomy. Cytoreduction and anticoagulants are
recommended prophylactic measures before splenectomy. Platelet
count should be kept below 400  109/L because of the potential
for postoperative extreme thrombocytosis. An experienced surgi-
cal team is recommended.
AlloSCT. AlloSCT is currently the only treatment approach
in myelofibrosis that is potentially curative, but it is complicated
by relatively high treatment-related mortality and morbidity.
The estimated 1-year treatment-related mortality associated with
conventional-intensity conditioning alloSCT is approximately 30%,
and overall survival is 50%; with reduced-intensity conditioning al-
loSCT, 5-year median survival is estimated at 45% with a similar
incidence of treatment-related and relapse-related death rates.63-66 By
comparison, in a recent study of transplantation-eligible patientswith
PMF(high-or intermediate-riskpatients, age60years)whodidnot
undergo transplantation, the 1- and 3-year survival rates ranged from
71% to 95% and 55% to 77%, respectively.67
It is reasonable to justify the risk of alloSCT-related complica-
tions inotherwise transplantation-eligiblepatientswhosemedian sur-
vival is expected to be less than 5 years. This would include IPSS
Table 5. Clinical Issues in Patients With Primary Myelofibrosis
Issue
Shortened survival
Increased risk of leukemic transformation, which approaches 20% in the
first 10 years of disease
Severe anemia often requiring frequent RBC transfusions and poor post-
transfusion increments because of associated marked splenomegaly;
some patients also have severe thrombocytopenia or neutropenia
Marked hepatosplenomegaly often accompanied by early satiety, severe
abdominal discomfort, changes in bowel habits, painful splenic
infarcts, portal hypertension leading to ascites and variceal bleeding,
compromised mobility and movement, and cachexia
Nonhepatosplenic extramedullary hematopoiesis that might lead to cord
compression, ascites, pulmonary hypertension, pleural effusion,
lymphadenopathy, or skin tumors
Thrombohemorrhagic complications
Marked leukocytosis or thrombocytosis
Profound constitutional symptoms including fatigue, weight loss, cachexia,
pruritus, night sweats, low-grade fever, and bone and joint pain
Recurrent gout
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high-risk (median survival, approximately 27months) or intermediate-
2–risk (median survival, approximately 48months)patients, aswell as
patients with either RBC transfusion need (median survival, approx-
imately 20 months) or unfavorable cytogenetic abnormalities (me-
dian survival, approximately 40 months). Other additional adverse
factors of outcome from alloSCT, including RBC transfusion load,
presenceofmarked splenomegaly, useof anon–HLA-identical sibling
donor, increased alloSCT-specific comorbidity index, advanced age,
advanced stage of disease, and unrelated donor who is not fully HLA
matched, must be considered. If alloSCT is a therapeutic option, a
physician with extensive experience in allogeneic transplantation
should be consulted.
Monitoring response. In the setting of alloSCT, monitoring
JAK2V617F allele burden has been shown to be useful in predicting
relapse.68,69 In other scenarios, it is reasonable to use cytogenetic
studies, JAK2 or MPL mutant allele burden, spleen size, blood count,
peripheral-blood leukoerythroblastosis, serumlactatedehydrogenase,
circulating CD34 cells, and bone marrow morphology and fibrosis
for assessing disease activity in PMF. The value of morphology or
molecular studies inmonitoring response to specific therapymust be
evaluated in a prospective setting.
Treatment of Blast-Phase MPN
Blast-phase MPN is a terminal disease with short survival (me-
dian survival, 6months) and limited therapeutic options.70 Results
of any treatment for blast-phase MPN are extremely poor. Experi-
mental or palliative therapy should be considered. Selected candidates
shouldbeconsidered for aggressive inductionchemotherapy followed
by consolidation with alloSCT. In candidates for transplantation,
complete remissionmaynotbe required toproceed to transplantation
as long as the disease reverts to chronic phase.
Special Issues in MPNs
Children. MPNs are rare in children, and ET is the most fre-
quent. By definition, children with ET are a low vascular risk popula-
tion unless a major thrombotic or hemorrhagic event has already
occurred. Thus, cytoreductive therapy is seldom indicated. Adverse
effects of INF- such as flu-like syndrome, neuropsychiatric symp-
toms, andautoimmunephenomena canbeparticularly dangerous for
children. Long-term leukemogenicityofhydroxyureamaybea special
concern for children, although none of the pediatric patients with
MPN treated with this agent have undergone malignant transforma-
tion to date.
Diagnostic criteria ofMPNs in children are the same as in adults,
but family screening is recommended to differentiate JAK2V617F-
negative ET from rare familial disorders caused by mutations of
TPO or MPL other than W515, particularly MPLS505N. In addi-
tion, in case of JAK2V617F-negative or exon 12–negative erythro-
cytosis with normal or reduced serum erythropoietin levels, a
familial history should prompt search for rare mutations in eryth-
ropoietin receptor. Screening for inherited thrombophilia is
recommended in patients with familial or personal history of
thrombosis. Cytoreductive drugs should be used only as a last
resort. There are insufficient data to recommend a specific agent,
and the choice should be made on individual basis. Use of aspirin
in children younger than 12 years of age should be considered with
caution because of the risk of Reye’s syndrome.
Hereditary predisposition. A recent large epidemiologic study
found that the risk of any MPN is five- to seven-fold elevated among
first-degree relatives of patients with MPN compared with control
population, supporting the existence of susceptibility gene(s) predis-
posing toMPNs.71A strongassociationbetween the riskofdeveloping
a JAK2V617F-positive MPN and a germline haplotype (46/1 or
GGCC; odds ratio, three- to four-fold), that includes the 3 portion of
the JAK2 gene itself, has been recently described.72-74 It has been
calculated that this haplotype accounts for half theMPN risk attribut-
able to inherited factors.
Heightened awareness of familial occurrence of MPNs should
alert physicians to acquire as much relevant information as possible
concerning relatives in any patient with novel, apparently sporadic
MPNto exclude apreviouslyunrecognizedMPNkindred.There is no
evidence of germline transmissionof JAK2V617Fmutation, and there
is no indication to routinely genotype for JAK2 mutations or JAK2
46/1 (GGCC) haplotype in relatives of individuals with MPNs in the
absence of hematologic or clinical abnormalities.
Pregnancy. The presence of a Ph-negative classical MPN in-
creases the risk ofmiscarriages and other complications of pregnancy,
such as abruptio placentae, pre-eclampsia, and intrauterine growth
retardation. Fetal loss in women with ET is approximately three to
four times higher compared with the general population; risk factors
include previous pregnancy complications and possibly the presence
of JAK2V617Fmutation. Venous thrombosis may occur, particularly
in the postpartum period, and the risk is higher in patients with a
history of vascular events.75-77 Treatment options include no therapy,
phlebotomy, aspirin, low molecular weight heparin, and IFN-, but
evidence for therapeutic recommendations is limited.Features consis-
tentwith high-riskMPNpregnancy and treatment recommendations
are listed in Table 6.
Splanchnic vein thrombosis. Abdominal vein thrombosis, in-
cluding extrahepatic portal vein occlusion, Budd-Chiari syndrome,
Table 6. Treatment Strategy for Philadelphia-Negative Classical
Myeloproliferative Neoplasms in Pregnancy
Pregnancy Risk Therapy
Low-risk
pregnancy
Target hematocrit in polycythemia vera should be kept
to  45% or midgestation-specific range, whichever
is lower; low-dose aspirin; prophylactic dose low
molecular weight heparin after delivery until 6 weeks
postpartum
High-risk
pregnancy
As above, plus:
1. If previous major thrombosis or severe pregnancy
complications: low molecular weight heparin
throughout pregnancy (stop aspirin if bleeding
complications)
2. If platelet count  1,500  109/L: consider interferon
alfa
3. If previous major bleeding: avoid aspirin and consider
interferon alfa to reduce thrombocytosis
Features consistent with high-risk myeloproliferative neoplasm pregnancy
include previous venous or arterial thrombosis (whether pregnant or not);
previous hemorrhage attributed to myeloproliferative neoplasm (whether
pregnant or not); previous pregnancy complication that may have been caused
by myeloproliferative neoplasm, such as unexplained recurrent first-trimester
loss (three unexplained first-trimester losses), intrauterine growth restriction
(birth weight  fifth percentile for gestation), intrauterine death or stillbirth
(with no obvious other cause, evidence of placental dysfunction, and growth-
restricted fetus), severe pre-eclampsia (necessitating preterm delivery  34
weeks), or development of any such complication in the index pregnancy;
placental abruption; significant ante- or postpartum hemorrhage; and marked
sustained increase in platelet count to greater than 1,500  109/L.
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andmesenteric vein thrombosis, is frequently encountered inMPNs.
Here, MPNmay not be clinically obvious because concurrent hyper-
splenism, occult GI bleeding, or hemodilution can mask the blood
count abnormalities. Diagnostic procedures include computed to-
mography scan, hepatic ultrasonography, angiography, and bone
marrowbiopsy.Ofdiagnostichelp is thedeterminationof JAK2V617F
mutation, which is found in approximately 45% of patients with
Budd-Chiari syndrome and 34% of patients with portal vein throm-
boses.78 Intensive management including transjugular intrahepatic
portosystemic shunt, angioplasty with or without stenting, surgical
shunts, and liver transplantation should be considered in the most
severe cases.
Treatmentof splanchnicvein thrombosis includes lowmolecular
weight heparin followed by long-life oral anticoagulation with inter-
national normalized ratio in the range 2.0 to 3.0. Joint management
with liver team, follow-up of varices, and warning about pregnancy
are recommended in this context. For patients with thrombocytosis,
hydroxyurea should be used to restore counts to  400  109/L as
soon as possible.
Pruritus. Intractablepruritus, typically aquagenic, can represent
adisablingcondition in somepatientswithMPN,particularlyPV.The
pathogenesis is unknown, although JAK2V617F-induced constitutive
activation and agonist hypersensitivity in basophils of these patients
have been recently demonstrated.79
Antihistamines, such as cyproheptadine 4 to 16mg/d, may be of
benefit. Ifunsuccessful, IFN-3.0106Usubcutaneously three times
aweek or pegylated IFN 0.5 to 1.0g/kg/wk is reported to be effective
in themajority of patients. Other treatment options include the selec-
tive serotoninuptake inhibitorparoxetine (20mg/d)andphotochem-
otherapy using psoralen and ultraviolet A light.
Pulmonary hypertension. Ph-negative classical MPNs associ-
ated with pulmonary hypertension (PH) are included in the group
5 category, corresponding to PH for which the etiology is unclear
and/or multifactorial.80 The following two major distinct clinical
forms of PH have been described in patients with MPNs: chronic
thromboembolic PH and precapillary PH mimicking pulmonary
idiopathic arterial hypertension. Diagnosis of PH should be estab-
lished as recommended by expert guidelines,81 and a technetium-
99m sulfur colloid scintigraphy should be specifically used for
documenting precapillary PH as a result of diffuse occult pulmo-
nary EMH. Pulmonary endarterectomy is the treatment of choice
in patients with chronic thromboembolic PH. In PH that is inac-
cessible to surgery,medical therapy including diuretics, anticoagu-
lants, and antihypertensive drugs such as sildenafil should be
considered. In patients with high thrombotic risk, cytoreductive
therapy with hydroxyurea is recommended. Case reports suggest
that in patients with MPNs and PH with EMH, a treatment trial
with whole-lung, low-dose, external-beam radiotherapy may be a
useful palliation.82
The final examination in patients with PH associated with
Ph-negative classical MPNs is right heart catheterization, which is
useful to differentiate different types of PH. In the case of idio-
pathic PH of PMF, pulmonary bonemarrow scan is recommended
to document pulmonary EMH. Current treatment of choice is
radiotherapy for patients in whom the technetium scan shows
EMH involvement.
DISCUSSION
This document is mainly based on the experience and knowledge of
experts in thefield coordinatedby themethodsof groupdecision.The
rationale of current therapy for Ph-negative classical MPNs is to pre-
vent the risk of thrombosis or hemorrhage in PV and ET and to
address thepresentingmajorclinical issues inPMF. Invasive therapies,
such as splenectomy and alloSCT in PMF, are used in the setting of
failed drug therapy and for patients with advanced disease.
Many research issues are open in Ph-negative classical MPNs.
The difficulties in dissecting the continuumof clinical phenotypes are
reflected in the recently revised WHO classification,5 which arranges
hematologic, morphologic, andmolecular parameters to separate the
three clinical disorders. Although this classification has endorsed
the concept of prefibrotic early stage of PMF to capture the step-
wise evolution of the diseases, the boundary between so-called true
ET and prefibrotic PMF is uncertain, being currently based on
morphologic features, the reproducibility of which has been ques-
tioned.7 The definition of this issue can have conceptual, clinical,
and prognostic relevance.
Researchers in the field agree that new prognostic parameters
could help in planning early treatment for patients with Ph-negative
classical MPNs who now remain untreated. Leukocytosis and
JAK2V617F allele burden have been hypothesized to represent
disease-associated surrogate markers of increased thrombotic risk in
ET and PV83-87 andmerit validation in controlled trials.
Several investigational drugs are currently being evaluated in
symptomatic patients with Ph-negative classical MPNs. In a recent
phase II randomized study, oral pomalidomide (a second-generation
thalidomide analog) alone or with a tapering dose of prednisone
resulted in anemia response rates of up to 36%. At the effective dose
level of 0.5 mg/d, the drug did not cause either neuropathy or severe
myelosuppression.88 Its role in the treatment of anemia should be
tested in a controlledmanner.Verstovsek et al89 reported the results of
a phase I/II trial first using anoral JAK1/JAK2 inhibitor, INCB018424,
in patients with PMF. Themajority of the 153 patients with advanced
disease who received INCB018424 experienced an improvement in
constitutional symptoms, pruritus, and overall performance status.
The enlarged spleen at least halved in 50% of the patients at the
optimal drug dose, producing durable improvement in abdominal
discomfort, pain, and weight loss. Thus, results of this trial point to
JAK1/JAK2 inhibition as a novel therapeutic avenue for producing
unforeseen clinical benefits in myelofibrosis. Two ongoing phase III
studies, with either placebo (Controlled Myelofibrosis Study With
Oral JAK Inhibitor Treatment [COMFORT] -1; NCT00952289) or
best-available therapy control arms (COMFORT-2; NCT00934544),
will hopefully raiseour enthusiasm.Furthermore, thedrug couldhave
considerable efficacy in advancedPVorETrefractory tohydroxyurea,
according to a preliminary report of a phase II trial (NCT00726232).
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